Roche's Tecentriq wins fast FDA review in tough-to-treat breast cancer

Roche's Tecentriq medicine will get a speedy review by U.S. regulators in a tough-to-treat form of breast cancer as the Swiss drugmaker seeks to be the first company to have its immunotherapy win approval in this indication.